Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 - the protein targeted by drugs like Keytruda - had met its goal.

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an ...

Now, Gilead argues that the “significant and meaningful” improvement in progression-free survival as shown in Ascent-04 “further reinforces the potential of Trodelvy plus Keytruda as a much ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

After meeting the mark alongside Keytruda in triple-negative breast cancer earlier this year, Gilead’s ADC Trodelvy has impressed in a solo showing.

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.